Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats

World Journal of Gastroenterology

Volumn 14, Issue 14, 2008, Pages 2179-2186

  Wei, Zhi Gang ^a   Li, Guo Xin ^a   Huang, Xiang Cheng ^a   Zhen, Li ^a   Yu, Jiang ^a   Deng, Hai Jun ^a   Qing, Shan Hua ^a   Zhang, Ce ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; Carrier solutions; Intraperitoneal chemotherapy; Pharmacokinetics; Tissue distribution

Indexed keywords

FLUOROURACIL; HETASTARCH; SODIUM CHLORIDE; ANTINEOPLASTIC ANTIMETABOLITE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; COLON; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG LIVER LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY PARENCHYMA; LUNG PARENCHYMA; MALE; NONHUMAN; PERITONEAL FLUID; PORTAL VEIN; RAT; SPRAGUE DAWLEY RAT; STOMACH MUCOSA; ANIMAL; ASCITES FLUID; CHEMISTRY; INFUSION; LIVER; METABOLISM; METHODOLOGY; SOLUTION AND SOLUBILITY; STOMACH; TISSUE DISTRIBUTION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ASCITIC FLUID; CHEMISTRY, PHARMACEUTICAL; COLON; FEMALE; FLUOROURACIL; INFUSIONS, PARENTERAL; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; SOLUTIONS; STOMACH; TISSUE DISTRIBUTION;

EID: 49249120622     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.2179     Document Type: Article

References (30)

1. Ebert M, Xing X, Burgermeister E, Schmid R, Rocken C. Perspectives of clinical proteornics in gastrointestinal cancer. Expert Rev Anticancer Ther 2007; 7: 465-469
2. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87: 236-242
3. Yonemura Y, Bandou E, Kinoshita K, Kawamura T, Takahashi S, Endou Y, Sasaki T. Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am 2003; 12: 635-648
4. Sugarbaker PH. Adjuvant intraperitoneal chemotherapy: a review. Recent Results Cancer Res 2007; 169: 75-82
5. Cortesi E, Martello O, Padovani A. Role of intraperitoneal chemotherapy. Minerva Ginecol 2001; 53: 29-33
6. Mohamed F, Sugarbaker PH. Carrier solutions for intraperitoneal chemotherapy. Surg Oncol Clin N Am 2003; 12: 813-824
7. Myers CE, Collins JM. Pharmacology of intraperitoneal chemotherapy. Cancer Invest 1983; 1: 395-407
8. Rosenshein N, Blake D, McIntyre PA, Parmley T, Natarajan TK, Dvornicky J, Nickoloff E. The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol Oncol 1978; 6: 106-110
9. Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH. Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol 2001; 47: 269-276
10. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48: 4093-4100
11. Kerr DJ, Young AM, Neoptolemos JP, Sherman M, Van-Geene P, Stanley A, Ferry D, Dobbie JW, Vincke B, Gilbert J, el Eini D, Dombros N, Fountzilas G. Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution. Br J Cancer 1996; 74: 2032-2035
12. McArdle CS, Kerr DJ, O'Gorman P, Wotherspoon HA, Warren H, Watson D, Vinke BJ, Dobbie JW, el Eini DI. Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma. Br J Cancer 1994; 70: 762-766
13. Dobbie JW. New principles, better practices, and clearer perceptions in intraperitoneal chemotherapy: clinical experience using icodextrin 20 as a carrier solution. Adv Perit Dial 1997; 13: 162-167
14. Mohamed F, Marchettini P, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol 2003; 52: 405-410
15. Mohamed F, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions. J Surg Res 2003; 113: 114-120
16. Kraft AR, Tompkins RK, Jesseph JE. Peritoneal electrolyte absorption: analysis of portal, systemic venous, and lymphatic transport. Surgery 1968; 64: 148-153
17. Markman M. Intraperitoneal chemotherapy. Semin Oncol 1991; 18: 248-254
18. Mohamed F, Marchettini P, Stuart OA, Yoo D, Sugarbaker PH. A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. Eur J Surg Oncol 2003; 29: 261-265
19. Sugarbaker PH. Managing the peritoneal surface component of gastrointestinal cancer. Part 2. Perioperative intraperitoneal chemotherapy. Oncology (Williston Park) 2004; 18: 207-219; discussion 220-222, 227-228, 230
20. Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for regectable gastric cancer. Ann Surg Oncol 2007; 14: 2702-2713
21. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006; 24: 4011-4019
22. Litterst CL, Torres LJ, Sikic BI. Absorption of antineoplastic drugs following large volume administration to rats. Cancer Treat Rep 1980; 66: 147-155
23. Groose E, Walker L, Masters JR. The influence of osmolarity on drug cytotoxicity in vitro. Br J Cancer 1986; 54: 181
24. Los G, Verdegaal EM, Mutsaers PH, McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 1991; 28: 159-165
25. Tsujitani S, Fukuda K, Saito H, Kondo A, Ikeguchi M, Maeta M, Kaibara N. The administration of hypotonic intraperitoneal cisplatin during operation as a treatment for the peritoneal dissemination of gastric cancer. Surgery 2002; 131: S98-S104
26. Elias D, El Otmany A, Bonnay M, Paci A, Ducreux M, Antoun S, Lasser P, Laurent S, Bourget P. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology 2002; 63: 346-352
27. McArdle CS, Kerr DJ, O'Gorman P, Wotherspoon HA, Warren H, Watson D, Vinke BJ, Dobbie JW, el Eini DI. Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma. Br J Cancer 1994; 70: 762-766
28. Hosie K, Gilbert JA, Kerr D, Brown CB, Peers EM. Fluid dynamics in man of an intraperitoneal drug delivery solution: 4% icodextrin. Drug Deliv 2001; 8: 9-12
29. diZerega GS, Verco SJ, Young P, Kettel M, Kobak W, Martin D, Sanfilippo J, Peers EM, Scrimgeour A, Brown CB. A randomized, controlled pilot study of the safety and efficacy of 4% icodextrin solution in the reduction of adhesions following laparoscopic gynaecological surgery. Hum Reprod 2002; 17: 1031-1038
30. Pestieau SR, Marchettini P, Stuart OA, Chang D, Sugarbaker PH. Prevention of intrapentoneal adhesions by intrapentoneal lavage and intraperitoneal 5-fluorouracil: experimental studies. Int Surg 2002; 87: 195-200